Discover why Genmab's antibody platforms, growing royalties, and late-stage pipeline make it a top biotech stock for ...

Discussing ‘cure’ may risk oncologists’ credibility, should a patient’s ovarian cancer recur,” researchers wrote.

Cancer is cruel. It doesn’t care that you’re only 37, that you're the mother of a little girl who is your entire world. So Elissa vowed to fight.

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.

A landmark review, now published in the Journal of Experimental & Clinical Cancer Research, offers a sweeping and ...

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...

To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with clinically relevant samples. This resource also supports continuous process ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Cancer is the rapid, uncontrollable proliferation of mutated cells that spread within tissue and eventually throughout the body. Cancer types are dependent | Immunology ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...